CASE REPORT

Wells’ Syndrome Associated with Churg-Strauss Syndrome

Soo Hyun Lee, M.D., Mi Ryung Roh, M.D., Ph.D., Hyunjoong Jee, M.D.,
Kee Yang Chung, M.D., Ph.D., Jin Young Jung, M.D., Ph.D.

Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, 1Yeouido Oracle Cosmetic &
Dermatologic Surgery Clinic, Seoul, Korea

Churg-Strauss syndrome (CSS) is a multisystem granulomatous vasculitis that is characterized by peripheral eosinophilia and the infiltration of eosinophils into systemic organs. The skin lesions of CSS consist mainly of palpable purpura and nodules. Wells’ syndrome (WS) is a rare inflammatory dermatosis that is associated with recurrent granulomatous dermatitis and eosinophilia. Since these two diseases are rare, any overlap between them is very unusual. Herein, we report a patient with CSS, who initially presented a skin eruption of erythematous urticarial-plaques, vesicles, and blisters. Upon biopsy, the histology of these plaques indicated eosinophilic infiltration and “flame figures” within the dermis, which was consistent with a diagnosis of WS. Although the association between WS and CSS that was observed in our patient may be purely coincidental, it could also suggest a common pathogenic background of these two distinct diseases, as both share several many common features. (Ann Dermatol 23(4) 497∼500, 2011)

Keywords-Churg-Strauss syndrome, Flame figures, Wells’ syndrome

INTRODUCTION

Wells’ syndrome (WS), which was later named eosinophilic cellulitis, is a rare inflammatory dermatosis that was first described as a recurrent granulomatous dermatitis with concomitant eosinophilia by Wells in 1971. Although the pathophysiology of WS remains unclear, it is now believed to represent a specific hypersensitivity reaction to various exogenous and endogenous stimuli, such as insect bites, infections, drug eruption or underlying internal disorders. Conversely, Churg-Strauss syndrome (CSS) is a multisystem granulomatous vasculitis that primarily affects patients with asthma. Classically, CSS is characterized by interstitial eosinophilic infiltrates, extravascular granulomas, which occur in a variety of organs, and peripheral eosinophilia. To date, only four cases of overlap between these two diseases have been described. Here, we report a 57-year-old female with known CSS, who later developed a bullous skin eruption that was clinically and histologically consistent with WS.

CASE REPORT

A 57-year-old woman came to our clinic with multiple erythematous tense vesicles and blisters with secondary yellowish crusts on both forearms, as well as multiple pruritic, erythematous, and annular plaques on her trunk (Fig. 1). She reported a history of asthma, bilateral maxillary sinusitis, vasculitis, and peripheral sensory-motor polyneuropathy in the lower extremities, all of which fulfilled the American College of Rheumatology criteria for CSS. A skin biopsy from a blister on her arm revealed the presence of multiple intraepidermal vesicles and subepidermal blisters, with perivascular and interstitial infiltrations of lymphocytes and eosinophils in the super-
Fig. 1. (A) Both forearms contained multiple tense bullae based on erythematous patch with secondary yellowish crusts. (B) Multiple erythematous edematous annular plaques on the trunk, with some central darkening.

Fig. 2. (A) Multiple intraepidermal vesicles and subepidermal blisters with underlying perivenular and interstitial inflammatory cell infiltrations in the superficial and deep dermis (H&E, ×40). (B) Perivenular and interstitial infiltration of lymphocytes and eosinophils forming “flame figures” (H&E, ×400).

FICIAL AND DEEP DERMIS. NOTABLY, THESE INFILTRATIONS ALSO FORMED CHARACTERISTIC “FLAME FIGURE” AGGREGATES IN THE DERMIS, WHICH WAS CONSISTENT WITH A DIAGNOSIS OF WS (FIG. 2). SUBSEQUENT DIRECT IMMUNOFluoresCENCE MICROSCOPY DID NOT SHOW ANY IMMUNOGLOBULIN OR COMPLEMENT DEPOSITS IN THE LESIONAL SKIN. AN ADDITIONAL LABORATORY ANALYSIS REVEALED A WHITE BLOOD CELL COUNT OF 5.71 × 10⁹/L WITH PERIPHERAL EOSINOphILIA (24.3%), AN ERYTHROCYTE SEDIMENTATION RATE OF 112 mm/h, A C-reactiVe Protein level of 4.22 mg/dl, AND A NEGATIVE ANTI-NeuTrOPHIL CYTOSPLASMIC ANTIBODY (anti-MPO, p-ANCA). IN THE CHEST X-RAY AND CHEST COMPUTED TOMOGRAPHY (CT), A DIFFUSELY INCREASED OPACITY WAS NOTED IN BOTH LOWER LOBES, WHEREAS THE ECHOCARDiOGRAPHY AND ABDOMEN CT DID NOT INDICATE ANY ASSOCIATED PATHOLOGIES. THE PATIENT WAS SUBSEQUENTLY TREATED WITH ORAL PREDNISOLONE (1 mg/kg per day), WHICH RESOLVED THE BULLOUS SKIN LESIONS, AS WELL AS REDUCED THE PAIN AND PRURITUS FOR SEVERAL DAYS. THE ORAL PREDNISOLONE WAS SUBSEQUENTLY TAPERED OVER THREE WEEKS, AND, 1 WEEK AFTER DISCONTINUING ALL PREVIOUS MEDICATIONS, SHE REDEVELOPED THE SAME RASH. CONSEQUENTLY, TREATMENT WITH ORAL PREDNISOLONE WAS RESTARTED (1 mg/kg per day), AND AFTER A 1-MONTH TAPERING, THE SKIN LESIONS IMPROVED SIGNIFICANTLY.

She is currently under regular surveillance.

DISCUSSION

WS is a rare, often recurrent, inflammatory disorder that is characterized by indurated urticarial erythematous plaques, similar to those seen in cellulitis. Pathologically, the characteristic feature of WS is “flame figures”, which are histiocyte and giant cell aggregates surrounding collagen bundles that are coated with eosinophilic granules. These flame figures represent histological cutaneous reaction patterns specific to eosinophil-mediated dermatoses, most commonly WS, bullous pemphigoid, herpes gestationis,
Wells' Syndrome Associated with Churg-Strauss Syndrome

prurigo, eczema, or dermatophyte infections. WS can present either solitary or multiple cutaneous lesions, which typically resolve spontaneously after several weeks with some residual atrophy and hyperpigmentation. The other clinical manifestations of WS are quite diverse morphologically and range from cellulitis-like manifestations to less common bullous or vesicular lesions. Affected patients often develop recurrences months to years after the initial presentation, and peripheral eosinophilia with some residual atrophy and hyperpigmentation is present in about 50% of all cases.

CSS is characterized by the constellation of severe asthma, fever, hypereosinophilia, and symptoms of vascular impairment in various organ systems. Although the pathogenesis of CSS remains unknown, it is now classified as a form of ANCA-associated small-vessel vasculitis (even though ANCA is present in less 50% of patients), and most current data suggest that CSS is induced by some allergenic or environmental trigger in pre-sensitized patients with asthma. Since CSS is primarily a clinical diagnosis, the American College of Rheumatology has established six separate criteria to facilitate the identification of affected individuals:

1. Asthma (defined as a history of wheezing or diffuse, high-pitched wheezes upon expiration),
2. Eosinophilia of >10% in differential white blood cell counts,
3. Mononeuropathy (including multiplex) or polyneuropathy,
4. Migratory or transient pulmonary opacities detected radiographically,
5. The presence of paranasal sinus abnormalities and (6) histologic evidence of perivascular eosinophil accumulation.

In individuals with documented vasculitis, the presence of four or more of these criteria yields a diagnostic sensitivity and specificity for CSS of 85% and 99.7%, respectively. In the case of our patient, all criteria were fulfilled. Notably, the involvement of skin in CSS is not rare, occurring in roughly 40–70% of all patients, and classically presents as erythematous maculopapules, haemorrhagic lesions, or cutaneous and subcutaneous nodules, while bullous lesions are substantially less common. Histologically, CSS is characterized by a triad of systemic vasculitis, eosinophilic tissue infiltration, and extravascular granulomas. “Flame figures,” however, have never been described in CSS, except in case reports of CSS-related WS. Thus, in our case, the bullous lesions were considered to be a WS-related symptom. Bullae are frequently present in WS, and in most cases, they develop on top of urticarial erythematous plaques and atop a small area of the plateau.

Hypothetically, CSS could induce WS via the pathogenic affects of the associated eosinophils that infiltrate through the skin. It is assumed that the eosinophilic inflammatory processes that target the skin, nerves, and blood vessels result from the underlying CSS pathophysiology. Accordingly, when diverted into the skin, which is possibly due to an additional unknown trigger, these same processes may produce “flame figures” historically, and the bullous form of WS clinically.

Interestingly, Churg and Strauss suggested in their initial report that WS may be related to CSS, due to the similarity of the histopathologic changes associated with both conditions. In regards to the treatment of CSS with WS, we found that prednisolone at a dose of 1 mg/kg was an effective therapeutic regimen.

Notably, in all reported cases of CSS/WS overlap, CSS always preceded WS, suggesting that WS should be considered in the differential diagnosis of patients with CSS whose clinical presentation includes erythematous urticarial plaques. Although the association between these two conditions may be purely coincidental, it could also represent a common pathogenetic background, since both WS and CSS share many main features, including peripheral and/or tissue eosinophilia and widespread eosinophilic infiltration into multiple organs.

REFERENCES

1. Wells GC, Smith NP. Eosinophilic cellulitis. Br J Dermatol 1979;100:101-109.
2. Schuttelaar ML, Jonkman MF. Bullous eosinophilic cellulitis (Wells’ syndrome) associated with Churg-Strauss syndrome. J Eur Acad Dermatol Venereol 2003;17:91-93.
3. Lee SC, Shin SS, Lee JB, Won YH. Wells syndrome associated with Churg-Strauss syndrome. J Am Acad Dermatol 2000;43:556-557.
4. Govoni M, Colina M, Cavazzini L, Trofta F. Churg-Strauss syndrome and Wells syndrome: coincidence or pathogenetic association? A new case report. Clin Exp Rheumatol 2007;25(1 Suppl 44):541.
5. Fujimoto N, Wakabayashi M, Kato T, Nishio C, Tanaka T. Wells syndrome associated with Churg-Strauss syndrome. Clin Exp Rheumatol 2011;36:46-48.
6. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angitis). Arthritis Rheum 1990;33:1094-1100.
7. Katoulis AC, Bozi E, Samara M, Kalogeromitros D, Panayiotides I, Stavrianeas NG. Idiopathic bullous eosinophilic cellulitis (Wells’ syndrome). Clin Exp Dermatol 2009;34:e375-e376.
8. Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol 2006;142:1157-1161.
9. Gilliam AE, Bruckner AL, Howard RM, Lee BP, Wu S, Frieden IJ. Bullous "cellulitis" with eosinophilia: case report and review of Wells’ syndrome in childhood. Pediatrics
10. Churg J, Strauss L. Allergic granulomatosis, allergic angitis, and periarteritis nodosa. Am J Pathol 1951;27:277-301.

11. Kallenberg CG. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 2005;52:2589-2593.